标题 |
Efficacy and safety of subcutaneous brodalumab, a fully human anti–IL- 17RA monoclonal antibody, for systemic sclerosis with moderate-tosevere skin thickening: a multicenter, randomized, placebo-controlled, double-blind phase 3 study
皮下注射brodalumab(一种全人源抗IL-17Ra单克隆抗体)治疗伴有中度至重度皮肤增厚的系统性硬化症的疗效和安全性:一项多中心、随机、安慰剂对照、双盲3期研究
|
网址 |
求助人暂未提供
|
DOI |
暂未提供,该求助的时间将会延长,查看原因?
|
其它 | 2022 Congress held from June 1 to June 4, 2022. abstracts |
求助人 | |
下载 |